Upstream Processing

A review of key industry shifts and promises for the future.

Charles H. Squires of Pfenex discusses advances in expression platform solutions.

Formulators and developers are at the heart of the industry's basic premise-they are saving lives.

Industry experts discuss significant achievements. Plus: What's in store for the future.

The author highlights novel strains and methods that have recently been shown to express multidisulfide bonded proteins.

This article discusses potential opportunities to improve the patient experience through formulation and delivery device technologies.

The author describes expression technology that produces cell lines with high genetic stability.

MAb polishing using salt tolerant interaction membrane chromatography.

A Q&A with Alan Shaw of Vaxinnate. This article is part of a special section on expression systems.

Industry experts discuss the benefits and challenges of self-administration of injectable therapies.

A technical rountable featuring Sartorius Stedim Biotech, Pall Life Sciences, 3M Purification, Asahi Kasei Bioprocess, and Bio-Rad Laboratories.

The authors describe a new assembly for bulk and final drug product filling operations.

BioPharm talks with Tarja Mottram, CEO of Action for Results, about key business considerations when starting out.

Demonstration of large-scale stem-cell scale-up.

Recombinant albumin can stabilize a drug product and assist in API release.

Key technical considerations when developing a clinical project in the biotech world.

This month, we revisit "Industrial-Scale Mammalian Cell Culture, Part I: Bioreactor Design Considerations."

Recombinant technology can be used to produce conjugate vaccines.

Readers react to the economic turmoil of the past year and look longingly forward to 2012.

New technology is designed to improve production efficiency by taking advantage of the properties of single-use bags.

Biosimilar manufacturers need better expression systems and analytical tools to compete.

Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs.

An evaluation of the technologies needed to develop a safe, effective, and economically efficient vaccine. This article is part of a special section on vaccines.

Development of the ideal DNA vaccine requires the optimization of delivery strategies and plasmid vectors.

A survey provides insight into drug companies' plans for spending on outsourced services. This article contains bonus online material.